InspireMD receives U.S. patent for SwitchGuard NPS; IDE submission planned for 2024

InspireMD, Inc.

U.S. Patent No. 11,844,893 issued for 'Shunts with Blood Flow Indicators' covering SwitchGuard NPS.
SwitchGuard NPS designed to reverse blood flow and filter embolic debris during carotid stenting.
Company expects to submit IDE to FDA in 2024 to initiate clinical trial for SwitchGuard NPS with CGuard Prime.
CMS expanded coverage for carotid artery stenting to asymptomatic and standard risk patients in October 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.